AI Health
4 German AI Health Startups Applying AI From Research to Patient Support
DealBio tracks early-stage AI health startups across Europe and North America. These 4 German startups apply AI to clearly defined decisions across research, genomic interpretation, patient communication and preventive health.
- Germany
- Diagnostics
- Drug Discovery
- Digital Health
- Preventive Health
AI in health is becoming more specialized. The useful distinction is increasingly not whether a startup uses AI, but which decision the model improves, what data it needs and who acts on the output.
Across this group, AI is being embedded into recurring health and life-science decisions where speed, clarity and prioritization matter. The common thread is practical application: turning complex genomic, protein, clinical and preventive-health data into outputs that specialists, patients or employees can use.
At a Glance
01
Bioklar
Software that helps specialists identify disease-causing variants in genome data.
- Country
Germany- Founded
- 2026
- Sector
- Diagnostics
- Funding stage
- Seed or earlier
- Founders
Why Bioklar stands out
Bioklar is translating specialist genomics work into a live software workflow. Its Varklar platform is already available in public beta, and the German Cancer Research Center lists Bioklar and Varklar through its innovation-management activity.
Founder Anand Mayakonda also created maftools and authored the peer-reviewed Bioinformatics paper behind it. That track record matters because Varklar sits in the same broad problem space: turning large genomic datasets into evidence that a specialist can review and act on.
What Bioklar is building
Varklar helps specialists prioritize genetic variants that may explain a rare disease. It combines a patient's phenotype, meaning observable clinical characteristics, with genomic evidence so reviewers can focus first on the variants most consistent with the case.
The software also organizes evidence used in ACMG/AMP variant-classification guidelines and keeps the reasoning visible for expert review. AI supports the workflow, but the final interpretation remains with the specialist.
02
Orbion
Using AI to predict protein expression, stability and developability before lab work.
- Country
- Germany
- Founded
- 2025
- Sector
- Biotech
- Funding stage
- Seed or earlier
- Founders
Why Orbion stands out
Orbion is applying AI to a specific experimental decision: which protein constructs are most likely to express well and remain stable before a team spends time making them in the lab. QAI Ventures invested in the startup in January 2026.
Co-founder Çağlar Bozkurt brings repeat-founder and product experience from Twentify, which reached more than 100 enterprise customers, as well as later product roles at Taxfix and AMBOSS. That operating background complements Aniruddh Goteti's production machine-learning experience.
What Orbion is building
Orbion's subscription software scores protein sequences for expression, stability and developability, the set of properties that influence whether a candidate can be produced and handled reliably. Teams can compare constructs or mutations before committing to experimental production.
The product is aimed at biotech, pharmaceutical and research teams working on difficult proteins. Its value proposition is fewer failed experimental iterations and a shorter path to a usable protein sample.
Turning medical reports into plain-language explanations for patients.
- Country
- Germany
- Founded
- 2024
- Sector
- Digital health
- Funding stage
- Seed or earlier
- Founders
Why DocToRead stands out
DocToRead has already moved into real use: its patient app has been used thousands of times, and it operates a browser portal for clinics and practices. That gives the product two distribution paths around the same problem, one patient-facing and one integrated into clinical communication.
Founder Bastian Hollmann brings more than two decades of medical-technology and radiology experience and previously founded Hollmann Medical. His earlier work gives DocToRead direct familiarity with how medical information is produced and explained in clinical settings.
What DocToRead is building
Patients photograph or upload medical reports and receive a plain-language explanation that can be read aloud, saved or shared. Optical character recognition, software that converts text in an image into machine-readable text, captures the document before AI simplifies the language.
The clinician portal can generate concise, multilingual or child-friendly versions from the same source material. The aim is to reduce the gap between a technically correct report and a patient's ability to understand what it says.
04
GoEcoFit
Building an AI workplace health platform for personalized prevention and wellbeing.
- Country
- Germany
- Founded
- 2023
- Sector
- Digital health
- Funding stage
- Seed or earlier
- Founders
Why GoEcoFit stands out
GoEcoFit has moved from a consumer wellness proposition into a defined employer channel. In 2026, the startup signed a one-year contract with BioPark Regensburg covering its platform and two metabolomics analyses for participating employees.
An exclusive partnership with lifespin adds laboratory metabolomics, the measurement of small molecules produced by metabolism, to the platform. That gives GoEcoFit a way to combine lifestyle data with objective biological measurements in a workplace-prevention model.
What GoEcoFit is building
GoEcoFit combines health questionnaires, lifestyle tracking, coaching content and biomarker data in one preventive-health platform for employees. AI is used to organize inputs into personalized recommendations and priorities rather than present every data point with equal weight.
The platform can incorporate metabolomics results alongside daily behavior and wellbeing information. For employers, the product is packaged as a structured prevention program rather than a standalone consumer app.
Deal Sourcing for Investors
Looking for More Startups Like These?
DealBio helps investment teams discover, research, and monitor early-stage healthcare and life sciences startups aligned with their investment criteria.
Investment perspective
The common theme is narrow product scope. Bioklar and Orbion sit close to expert scientific workflows, where the model has to surface evidence or predictions that specialists can inspect. DocToRead and GoEcoFit sit closer to end users, where the challenge is turning complex information into something understandable and actionable.
That specialization gives investors a clearer way to evaluate AI health startups. Model novelty matters, but workflow fit, data quality, user trust and evidence of adoption determine whether the software becomes part of a repeated decision rather than a one-off demonstration.
Methodology
DealBio selected these startups from its coverage of early-stage health and longevity startups, focusing on German businesses where AI is central to a defined health or life-science workflow. The selection spans research, diagnostics, patient communication and prevention.
DealBio builds its Startup Briefs using publicly available startup materials, ecosystem sources, market references and professional profiles.